-- Advances Pipeline of RNAi Therapeutics with Phase II Results for ALN-RSV01, Continued Enrollment of ALN-VSP for Liver Cancer, and On Track to File IND for ALN-TTR for TTR-Mediated Amyloidosis --
CAMBRIDGE, Mass., Nov 04, 2009 (BUSINESS WIRE) --
-- Demonstrates Continued Strength of Partnerships, Including Year Five Extension with Novartis and Advanced Collaboration with Roche --
